Table 1.
Baseline characteristics of patients.
| All patients | HER2 0 group (N:111) | HER2 low group (N:49) |
||
|---|---|---|---|---|
| Characteristics | N (%) | N (%) | N (%) | P value |
| Age ≤65 >65 |
109 (68.1) 51 (31.9) |
77 (69.4) 34 (30.6) |
32 (65.3) 17 (34.7) |
.713 |
| Estrogen receptor expression Positive Negative |
160 (100) ‐(0) |
111 (100) |
49 (100) |
1 |
| Progesterone receptor expression Positive Negative |
151 (94.4) 9 (5.6) |
106 (95.5) 5 (4.5) |
45 (91.8) 4 (8.2) |
.355 |
| Menopause status Premenopausal Postmenopausal |
42 (26.2) 118 (73.8) |
29 (26.1) 82 (73.9) |
13 (26.5) 36 (73.5) |
.957 |
| Disease status De novo metastatic Recurrent disease |
77 (48.1) 83 (52.9) |
52 (46.8) 59 (53.2) |
25 (51) 24 (49) |
.732 |
| Visceral metastases Presence Absence |
65 (40.6) 95 (59.4) |
45 (40.5) 66 (59.5) |
20 (40.8) 29 (59.2) |
1 |
| Bone metastases Presence Absence |
124 (77.5) 36 (22.5) |
86 (77.5) 25 (22.5) |
38 (77.6) 11 (22.4) |
1 |
| Treatment agent Palbociclib Ribociclib |
63 (39.4) 97 (60.6) |
38 (34.2) 73 (65.8) |
25 (51) 24 (49) |
.054 |
| Endocrine therapy Aromatase inhibitors Fulvestrant |
121 (75.6) 39 (24.4) |
81 (73.0) 30 (27.0) |
40 (81.6) 9 (18.4) |
.318 |